Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nueva terapia para la depresión y otros trastornos psicóticos combinando el inhibidor selectivo de recaptación de serotonina y el Fragmento N-Terminal de Galanina (1-15)

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20180918002
Publicado:
30/10/2018
Caducidad:
31/10/2019
Resumen:
Una universidad andaluza ha desarrollado un kit de GAL (1-15) en combinación con un inhibidor de recaptación de serotonina (SRI) capaz de elevar el nivel de serotonina extracelular para el tratamiento de la depresión y otros trastornos de ansiedad, afectivos, alimenticios y cognitivos. Los resultados del kit indican que GAL (1-15) mejora los efectos antidepresivos inducidos por la fluoxetina (FLX) actuando en complejos de heteroreceptores 5-HT1AR-GALR1-GALR2 y ofrecen la posibilidad de utilizar una combinación de ambos como nueva estrategia en el tratamiento de la depresión. La universidad busca compañías farmacéuticas con el fin de establecer acuerdos de licencia o cooperación técnica.

Details

Tittle:
New therapy for depression and other psychotic disorders by combination of selective inhibitor of Serotonin re-uptaking and Galanin N-Terminal Fragment (1-15)
Summary:
An Andalusian University in the south of Spain has developed a kit of GAL (1-15) in combination with a serotonin reuptake inhibitor (SRI), which is able to cause an elevation in the level of extracellular serotonin for depression treatment and other anxiety-affective-eating-cognitive disorders. They are looking for pharmaceutical companies that want to enter into a licensing agreement or alternatively technical agreement.
Description:
An Andalusian University in the south of Spain has developed a combination kit of GAL (1-15) or a pharmaceutically acceptable salt therof useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin. Particularly, improving and/or potentiating the therapeutic effect of SRI or a compound, which causes an elevation in the level of extracellular 5-HT. The present invention is useful for the treatment of depression, anxiety disorders, and other affective disorders, eating disorders (such as bulimia, anorexia and obesity), phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse.
The clinical studies on depression and anxiety disorders indicate that non-response to Selective Serotonin Reuptake Inhibitors (SSRI) is substantial, up to 30%. Another factor in antidepressant treatment is compliance, which has a rather profound effect on the patient´s motivation to continue pharmacotherapy. There are multiple factors in RRSI use: 1) sexual dysfunction is a side effect common and, 2) there is a delay in therapeutic effect, which the psychiatrists try to cope with an augmentation strategy, which causes other problems.
The results of the kit indicate that GAL (1-15) enhances the antidepressant effects induced by Fluoxetine (FLX) probably acting on 5-HT1AR-GALR1-GALR2 heteroreceptor complexes and open up the possibility to use a combination of both as a novel strategy for treatment of depression.
Advantages and Innovations:
Lower doses of SSRIs:
The combination kit of GAL (1-15) with a serotonin reuptake inhibitor shows a synergistic effect on the central nervous system (CNS). As a consequence, combination therapy using GAL (1-15) and lower doses of the serotonin reuptake inhibitor than normally used in monotherapy, may be effective, and side effects associated with the larger amounts or serotonin reuptake inhibitor used in monotherapy may be reduced or prevented altogether.

Alternative for patients, who do not respond to conventional monotherapy:
Additionally, the combination therapy with GAL (1-15) using a normal dose of serotonin reuptake inhibitor has the advantage that an effective CNS effect may be obtained in the often large number of patients who do not respond to conventional monotherapy with SSRIs.
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
Pharmaceutical companies that want to enter into a licensing agreement or alternatively technical agreement in order to explore the new alternative possibility in antidepressant treatments.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001 Medicina, salud humana